stockrow
Saturday 7 November 2026
Export LABT’s income statement to Excel — free account
Lakewood-Amedex Biotherapeutics Inc.
LABT Healthcare Biotechnology
0.39
0.15
−27.78%
Follow LABT
Alert me
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
1.55 | 0.13 |
Net Debt/EBITDA |
0.17 | 0.06 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.83 | 0.33 |
Capex/Depreciation |
(0.03) | 0.00 |
Interest Coverage |
(805.36) | (37.39) |
| 0.00% | 749.24% | |
| 0.00% | (753.49%) | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(2,386.22%) | 279.73% |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(8.29) | (2.79) |
Cash per Share |
0.99 | 0.34 |
Shareholders Equity per Share |
0.59 | (2.82) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
0.59 | (2.82) |
Free Cash Flow |
(5.73) | (1.94) |
Working Capital |
0.27 | (2.10) |
Capital Expenditures |
0.00 | — |
Net Current Asset Value |
0.11 | (2.14) |
| Other line items | ||
Quick Ratio |
1.36 | 0.10 |
Depreciation/Fixed assets |
3.75 | 13.04 |
Cash ROIC |
(524.90%) | 112.53% |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(8.28) | (2.79) |
Capex per Share |
0.00 | 0.00 |
Average Payables |
— | 0.27 |
Average Assets |
— | 0.78 |
Average Common Equity |
— | (0.78) |
Capex to Sales |
0.00 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026